Analysis on sensitivity of β-lactam/β-lactamase inhibitors to bifidobacteria and lactobacilli / 重庆医学

Objective To analyze the susceptibility situation of bifidobacteria and lactobacilli from child intestinal tract on β-lactam/β-lactamase inhibitor complex.Methods According to the method of the Bergey Bacterial Identification Manual,45 strains of bifidobacteria and 39 strains of lactobacilli were isolated from the stool specimens of 36 healthy children.The susceptibility tests of bifidobacteria and lactobacilli to ampicillin,amoxicillin/clavulanate,ampicillin/sulbactam,piperacillin,piperacillin/tazobactam,ticarcillin,ticarcillin/clavulanate,cefoperazone and cefoperazone/sulbactam were performed by adopting the E-test method.Then the statistical analysis was conducted.Results The sensitivity percentages of 45 strains of bifidobacteria to ampicillin,amoxicillin/clavulanate,ampicillin/sulbactam,piperacillin,piperacillin/tazobactam,ticarcillin,ticarcillin/clavulanate and cefoperazone were 77.78％,95.56％,88.89％,73.33％,91.11％,68.89％,84.44％ and 82.22％ respectively,which of 39 strains of lactobacilli to above antibiotic drugs were 74.36％,94.87％,92.31％,71.79％,92.31％,69.23％,89.74％ and79.49％,respectively.Except having no judgment due to without the CLSI drug susceptibility MIC interpretation criteria of cefoperazone/sulbactam,the sensitivity percentages of other β-lactam/β-lactamase inhibitor complex were higher than those of single β-lactam antibi otics,the sensitive number P values of bifidobacteria in ampicillin with amoxicillin/clavulanate and piperacillin with piperacillin/tazobactam were 0.01 and 0.03 respectively,which of lactobacilli in ampicillin with amoxicillin/clavulanate,ampicillin with ampicillin/sulbactam,piperacillin with piperacillin/tazobactam,ticarcillin with ticarcillin/clavulanate were 0.01,0.03,0.02 and 0.03 respectively.Conclusion β-lactam/β-lactamase inhibitors complex has stronger effect for inhibiting child intestinal tract bifidobacteria and lactobacilli than single β-lactam antibiotics.

Incidence and risk factor analysis of antibiotic-associated diarrhea of pediatric patients with severe bacterial pneumo-nia / 临床儿科杂志

ObjectiveTo investigate the incidence and risk factors of antibiotic-associated diarrhea (AAD) of pediatric patients with severe bacterial pneumonia.MethodsClinical data of 1086 pediatric patients with severe bacterial pneumonia from January 2010 through January 2014 were recruited. The incidence and risk factors of AAD were retrospectively analyzed. ResultsThe incidence of AAD in 1086 pediatric patients with severe bacterial pneumonia was 36.74%. The incidence of AAD in patients younger than 2 years old were higher than that in those older than 2 years, once or more times of mechanical venti-lation history were higher than that with no arrangements of this treatment, administering of combined antibiotics therapy were higher than that with single antibiotics, and the incidence of AAD due to amoxicillin/clavulanate, piperacillin/tazobactam, cefo- perazone/sulbactam in pediatric patients were 43.55%, 43.75%, and 45.03%, respectively. Three β-lactam/β-lactamase inhibitors above were risk factors of AAD through multivariate Logistic regression analysis.ConclusionThe high incidence of AAD in pediatric patients with severe bacterial pneumonia was associated with some risk factors, including younger than 2 years old, me-chanical ventilation, combined antibiotics therapy and administration of β-lactam/β-lactamase inhibitor (amoxicillin/clavulanate, piperacillin/tazobactam, cefoperazone/sulbactam).